Navigation Links
BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
Date:9/28/2011

tical significance (p=0.066).  This starting dose "phenomenon" is not dissimilar to what has been observed with other approved opioids."

Dr. Finn concluded, "We observed significant efficacy in the opioid experienced subset of patients and believe there is a clear pathway forward to determine the same in the opioid naive patients.  We are also pleased to see that the product was well tolerated and that no unexpected side effects were seen.  Our overall evaluation of the data in these two patient populations has given us valuable insight and confidence that we will use in commencing a new study."  

"While there is disappointment over missing the primary efficacy endpoint of this study, the many positive findings we observed gives us great confidence in our ability to ultimately bring this product to market for the treatment of chronic pain in a variety of patient types," stated Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  

"Opioid naive and opioid experienced patients make up nearly 75% of all people requiring treatment for pain.  Our strategy was to capture both populations in our product label through the conduct of one trial rather than performing separate studies" continued Dr. Sirgo.  "We had an unusually high placebo response in the naive group of patients while the experienced group of patients responded as we had anticipated.  With some tightening of the study entry criteria and a few design adjustments, we are confident we can complete a successful trial."  

"In short, we know buprenorphine works in treating pain.  This opportunity has never been an "if" but a "when", and this study affirms our belief in this regard," continued Dr. Sirgo.  "We continue to believe that BEMA Buprenorphine has the opportunity to be the first transmucosal product for the treatment of chronic pain to reach the marketplace.  Our previously announced market projections for
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
6. Derma Sciences Reports Second Quarter 2008 Results
7. Advanced Life Sciences Announces Second Quarter 2008 Financial Results
8. The Michigan Life Sciences Pipeline Adds More Resources On Its Website
9. Milestone Biosciences, LLC Further Strengthens Executive Management Team
10. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
11. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 Nashville Fertility ... was elected treasurer for the American Society for Reproductive ... knowledge and research in reproductive medicine. In his ... seat on the executive board and will have a ... Dr. Hill has actively supported ASRM since 1984 when ...
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/22/2014)... December 22, 2014 The Center ... leader of technical training across the life sciences industry, ... Management (SCDM) to provide the organization's members with ... —providing access to the more than 350 sessions across ... with 10% off when registering for a public ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... SPEX ) reported that the Nasdaq Stock Market ... common stock from the Nasdaq,Global Market to the Nasdaq ... on the Nasdaq Capital Market on November 11, 2008., ... market tier designations for,Nasdaq-listed stocks, and presently includes over ...
... Company Will Host a Conference Call Today To Discuss the Data ... ... (Nasdaq: SGMO ) announced today top-line data from its,SB-509-601 clinical ... Therapeutic(TM) program to develop SB-509 for diabetic,neuropathy (DN). The data demonstrate ...
... 10 /Xinhua-PRNewswire-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: ... distributor of high-quality,pharmaceutical grade glucose products in China, ... the three months ended September 30, 2008,after the ... 13, 2008.,Management will conduct a conference call on ...
Cached Biology Technology:Spherix Transfers Stock Listing to Nasdaq Capital Market 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 2Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 3
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... An international team of scientists, including researchers at Columbia University ... common malaria parasites require for survival at each stage of ... new approach to combating malaria, one of the world,s deadliest ... of the journal Nature . "Perhaps the ...
... 2013 A Ben-Gurion University of the Negev (BGU) study ... Stress Disorder (PTSD) if their mother is already afflicted. ... & Anxiety , while fewer than 10 percent (8.4 percent) ... fifth (21 percent) of their children presented PTSD symptoms. Children ...
... Spring Harbor, NY A team of researchers at Cold ... DNA called an enhancer element that enables cancerous blood cells ... that is incurable in 70% of patients. Just as ... new class of promising drugs one version of which ...
Cached Biology News:Study finds new vulnerability in malaria parasite 2Scientists discover how leukemia cells exploit 'enhancer' DNA elements to cause lethal disease 2Scientists discover how leukemia cells exploit 'enhancer' DNA elements to cause lethal disease 3
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
Request Info...
... Polyoxyethylene Lauryl Ether 30% ... Kathon Preservative. Surfactant. Clear ... immunohistochemistry is 1 mL ... solution added to 400 ...
Biology Products: